Advanced search
Publication Cover
Gynecological Endocrinology Volume 37, 2021 - Issue 6
Submit an article Journal homepage
93
Views
1
CrossRef citations to date
0
Altmetric
MENOPAUSE

Ospemifene in clinical practice for vulvo-vaginal atrophy: results at 3 months of follow-up of use

Carmen Pingarrona Hospital Quironsalud San Jose, Ginecología, Madrid, SpainCorrespondence[email protected]
View further author information
,
Pilar de Lafuenteb Instituto Palacios de Salud y Medicina de la Mujer, Instituto Palacios de Salud y Medicina de la Mujer, Madrid, SpainView further author information
,
Antonio María Ierulloa Hospital Quironsalud San Jose, Ginecología, Madrid, SpainView further author information
,
Silvia Poyo Torcala Hospital Quironsalud San Jose, Ginecología, Madrid, SpainView further author information
,
Carlos Javier Maroto Díaza Hospital Quironsalud San Jose, Ginecología, Madrid, SpainView further author information
&
Santiago Palaciosb Instituto Palacios de Salud y Medicina de la Mujer, Instituto Palacios de Salud y Medicina de la Mujer, Madrid, SpainView further author information
Pages 562-566 | Received 24 Apr 2020, Accepted 17 Nov 2020, Published online: 10 Dec 2020

References

  • Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790–1799.
  • Nappi RE, Palacios S, Panay N, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016;19(2):188–197.
  • Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA) - results from an international survey. Climacteric. 2012;15(1):36–44.
  • Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87–94.
  • Davila GW, Singh A, Karapanagiotou I, et al. Are women with urogenital atrophy symptomatic? Am J Obstet Gynecol. 2003;188(2):382–388.
  • Huang AJ, Moore EE, Boyko EJ, et al. Vaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factors. Menopause. 2010;17(1):121–126.
  • Palacios S, Cancelo Hidalgo MJ, González SP, et al. Genitourinary syndrome of menopause: Recommendations from the Spanish Society of Obstetrics and Gynecology. Prog Obstet Ginecol. 2019;62(2):141–148.
  • Bachmann GA, Komi JO, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480–486.
  • Portman DJ, Bachmann GA, Simon JA, et al. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20(6):623–630.
  • Portman D, Palacios S, Nappi RE, et al. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas. 2014;78(2):91–98.
  • Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019;26(6):611–621.
  • Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas. 1995;22(Suppl):S1–S5.
  • Sánchez F, Pérez Conchillo M, Borrás Valls JJ, et al. Design and validation of the questionnaire on Women's Sexual Function (WSF). Aten Primaria. 2004;34(6):286–292.
  • Ruiz MA, Pardo A, Rejas J, et al. Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q). Value Health. 2008;11(5):913–926.
  • Simon JA, Lin VH, Radovich C, Ospemifene Study Group, et al. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20(4):418–427.
  • Goldstein SR, Bachmann GA, Koninckx PR, Ospemifene Study Group, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173–182.
  • Simon J, Portman D, Mabey RG. Jr. Ospemifene Study Group. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas. 2014;77(3):274–281.
  • Cui Y, Zong H, Yan H, et al. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med. 2014;11(2):487–497.
  • Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18(2):226–232.
  • Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774.
  • Constantine GD, Simon JA, Pickar JH, et al. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause. 2017;24(4):409–416.
  • Nappi RE, Mattsson LA, Lachowsky M, et al. The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe. Maturitas. 2013;75(4):373–379.
  • Sievert LL, Obermeyer CM, Saliba M. Symptom groupings at midlife: cross-cultural variation and association with job, home, and life change. Menopause. 2007;14(4):798–807.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.